Remise en cause de la réalité d’une augmentation de la mortalité cardiovasculaire sous traitement par privation androgénique pour cancer de la prostate ?

1. 1.

   Buvat J, Maggi M, Gooren L, et al (2010) Endocrine aspects of male sexual dysfunctions. J Sex Med 7:1627–1656

   • PubMed
   • Article
   • Google Scholar
2. 2.

   Corona G, Rastrelli G, Monami M, et al (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165:1–18

   • Article
   • Google Scholar
3. 3.

   Punnen S, Cooperberg MR, Sadetsky N, Carroll PR (2001) Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 29:3510–3516

   • Article
   • Google Scholar
4. 4.

   Efstathiou JA, Bae K, Shipley WU, et al (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54:816–823

   • PubMed
   • CAS
   • Article
   • Google Scholar
5. 5.

   Efstathiou JA, Bae K, Shipley WU, et al (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27:92–99

   • PubMed
   • PubMed Central
   • Article
   • Google Scholar
6. 6.

   Von Eckardstein A, Wu FCW (2004) Testosterone and cardiovascular diseases. In Nieschlag E, Behre HM (eds) Testosterone Action, Deficiency, Substitution. Cambridge University Press, Cambridge, pp 297–332

   • Google Scholar
7. 7.

   McGrath KC, McRobb LS, Heather AK (2008) Androgen therapy and atherosclerotic cardiovascular disease. Vasc Health Risk Manag 4:11–21

   • PubMed
   • CAS
   • PubMed Central
   • Article
   • Google Scholar

Download references